43599
document
Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease . OBJECTIVE Autosomal dominant polycystic kidney disease ( ADPKD ) is progressive , resulting in end-stage kidney failure in most patients . Experimental and clinical studies have suggested that statins may slow the progression of chronic kidney disease in general and ADPKD specifically . MATERIAL AND METHODS This randomized open-label clinical trial was conducted to assess the effect of pravastatin 20 mg on kidney function and urinary protein excretion in patients with ADPKD . Sixty patients were initially recruited but 49 of these received either pravastatin 20 mg or no treatment for 2 years . Trial visits were conducted every 3 months , assessing kidney function by estimated glomerular filtration rate and 24 h urine creatinine clearance and urinary protein excretion . RESULTS There were no significant ( p > 0.05 ) changes in markers of kidney function or urinary protein excretion between groups over the 2 years despite a significant fall in total serum cholesterol in pravastatin-treated patients ( p = 0.029 ) . CONCLUSION This trial found that taking 20 mg pravastatin for 2 years had no significant effect on kidney function or urinary protein excretion in patients with ADPKD . The lack of statistical power limits the external validity of these findings . A larger , longer duration study using a higher dose of a more potent statin is required .
43600
Intervention_Pharmacological
pravastatin
43601
Intervention_Pharmacological
statins
43602
Intervention_Pharmacological
pravastatin
43603
Intervention_Pharmacological
pravastatin
43604
Intervention_Control
no treatment
43605
Intervention_Pharmacological
pravastatin-treated
43606
Intervention_Pharmacological
pravastatin
43607
Outcome_Physical
kidney function
43608
Outcome_Physical
urinary protein excretion
43609
Outcome_Physical
progression
43610
Outcome_Physical
chronic kidney disease
43611
Outcome_Physical
kidney function
43612
Outcome_Other
glomerular filtration rate
43613
Outcome_Other
24 h urine creatinine clearance
43614
Outcome_Other
urinary protein excretion
43615
Outcome_Other
changes
43616
Outcome_Physical
markers of kidney function
43617
Outcome_Physical
urinary protein excretion
43618
Outcome_Physical
kidney function
43619
Outcome_Physical
urinary protein excretion
43620
Participant_Condition
autosomal dominant polycystic kidney disease .
43621
Participant_Condition
Autosomal dominant polycystic kidney disease ( ADPKD )
43622
Participant_Condition
end-stage kidney failure in most patients .
43623
Participant_Condition
patients with ADPKD .
43624
Participant_Sample-size
Sixty patients
43625
Participant_Sample-size
49